Cigna's Struggles: Pharmacy Benefits and Stock Performance
Cigna Group Experiences Stock Decline
The Cigna Group (NYSE: CI) has seen a noticeable decline in its stock price following an announcement made during its earnings call. The company has forecasted margin pressures within its pharmacy benefit services for the upcoming two years. This news has raised concerns among investors, leading to a drop in stock value.
Introduction of a New Pharmacy Benefit Model
Cigna’s health services division, Evernorth, recently unveiled a rebate-free pharmacy benefit model aimed at reducing costs and enhancing transparency for its clients. This model is projected to be adopted by Cigna Healthcare for its fully insured lives starting in 2027 and will become the standard model for all Evernorth pharmacy benefits clients by 2028.
Strategic Client Support
During the earnings call, Cigna outlined its efforts to support clients operating heavily in government programs. Recognizing the financial strains they face, the company has proactively improved contract economic terms for these long-term strategic clients, demonstrating its commitment to partnership stability.
Financial Performance Overview
For the third quarter, Cigna reported impressive revenues of $69.74 billion, surpassing analysts' estimates of $67.11 billion. The 10% year-over-year growth was primarily driven by the performance of Evernorth Health Services, bolstered by solid growth in existing client relationships and specialty pharmacy sectors.
Adjusted Earnings and Income Reports
Cigna's adjusted earnings per share reached $7.83, exceeding projections of $7.65. However, the adjusted income from operations saw a slight decline of 1%, landing at $2.09 billion, which was primarily attributed to reduced contributions from Cigna Healthcare, albeit partially offset by growth in Specialty & Care Services.
Sales by Segment
Breaking down the sales performance, Evernorth Health Services generated $60.39 billion in third-quarter sales, reflecting a 15% increase. Pharmacy Benefit Services alone brought in $34.09 billion, while Specialty and Care Services accounted for $26.3 billion. It's worth noting that Cigna Healthcare segment sales declined by 18% to $10.76 billion, largely due to the Health Care Services Corporation (HCSC) transaction.
Excluding Transaction Impacts
If one excludes the impact of the HCSC transaction, Cigna’s quarterly revenues would have actually risen by 6%, driven by premium rate increases to mitigate anticipated medical costs. Additionally, the Cigna Healthcare Medical Care Ratio (MCR) was reported at 84.8%, an increase from 82.8% a year prior.
Customer Metrics
At the end of the quarter, Cigna had a total of 18.06 million medical customers, down from 19.05 million the previous year. Overall customer relationships numbered 182.49 million, marking a 2% increase when excluding the impact of the HCSC transaction. Notably, total pharmacy customers reached 122.5 million.
Future Projections
Cigna has reaffirmed its fiscal 2025 adjusted income per share guidance, targeting over $29.60, slightly lower than the market consensus of $29.63. The company anticipates that Evernorth’s adjusted income from operations could be at least $7.2 billion, alongside a projected $4.125 billion from Cigna Healthcare. The Cigna Healthcare Medical Care Ratio is projected to remain between 83.2% and 84.2%.
Challenges Ahead
Looking ahead, Cigna expects operating income for Evernorth to slightly decrease in 2026. While the specialty and care services are anticipated to grow towards the higher end of Cigna's long-term growth targets, a decline in pharmacy benefit services is a concern that could affect overall performance.
Cigna Stock Status
As of the latest publication, the Cigna Group's shares fell by 13.35%, trading at $259.19. This downturn has positioned the stock closer to its 52-week low of $256.89, indicating challenging market conditions.
Frequently Asked Questions
What caused Cigna's stock plunge?
The stock declined due to forecasts of margin pressures in Cigna's pharmacy benefit services announced during the earnings call.
When will Cigna implement the new pharmacy benefit model?
Cigna plans to adopt the new rebate-free model for fully insured lives beginning in 2027, with wider implementation in 2028.
How did Cigna perform in the third quarter?
Cigna reported revenues of $69.74 billion, beating analyst estimations and achieving a 10% increase year-over-year.
What were Cigna's earnings per share in the recent quarter?
The adjusted earnings per share for Cigna reached $7.83, surpassing expectations of $7.65.
What challenges does Cigna foresee in the near future?
Cigna expects slight declines in operating income for Evernorth and anticipates challenges in its pharmacy benefit services.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.